We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA WANTS DEVICE COMPANIES TO ISSUE RECALLS ELECTRONICALLY

FDA WANTS DEVICE COMPANIES TO ISSUE RECALLS ELECTRONICALLY

May 19, 2006

The FDA is encouraging device companies to use email and other forms of electronic communications such as fax or text messaging to announce voluntary recalls of FDA-regulated products and other important device safety information to the public.

All aspects of recall information can be handled through email or other electronic communication methods, the guidance indicates. Manufacturers can rely on other forms of communication if electronic follow-ups fail, the FDA says.

The guidance notes that electronic communications have a number of advantages over paper-based communications, such as shortening the time safety information becomes available to the public. Email and other electronic communication are cost effective and allow receipt or delivery to be automatically verified, the agency noted.

Moreover, email or other electronic communications are less likely to be discarded than traditional mail. For example, email systems set up in physicians' offices generally allow supplier communications to bypass spam filters.

The guidance offers more leeway in formatting of ecommunications recalls than it does for traditional paper recall letters, but recommends using methods such as marking an email message "Urgent." The communication should also not contain promotional material or links to other promotional materials, the guidance adds.

The complete guidance can be viewed at http://www.fda.gov/oc/guidance/electronic.html (http://www.fda.gov/oc/guidance/electronic.html).

(http://www.fdanews.com/ddl/33_20/)

KEYWORDS FDAnews Device Daily Bulletin

Upcoming Events

  • 15Apr

    Five Telltale Signs You’re Ready for an Electronic TMF System

  • 21Apr

    CDER’s Most Significant Guidance Priorities for 2021: Biosimilars/Biologics, Generics/Exclusivity, Real-World Evidence, Drug Development and Digital Health

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

  • 06May

    The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • CE mark

    Roche Receives CE Mark for Elecsys Cancer Test

  • team up

    Biogen and Bio-Thera Solutions Partner Over Actemra Biosimilar

  • FDA logo blue

    Former Indivor Executive Seeks FDA Hearing to Avoid Debarment

  • FDA clears text

    FDA Clears Activ Surgical’s Imaging Module for ActivEdge Platform

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing